Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.

Inclusion Criteria:

• Subjects diagnosed with type 2 diabetes previously treated with BHI for at least 12 months
• Analogue premix administration for the last 6 months

Exclusion Criteria:

• Known or suspected allergy to insulin aspart
• Newly diagnosed diabetes